Señales en vivo de IMTX | Maximiza tus Ganancias con Getagraph.com

VENDER 108731 min ago

@ $11.29

Emitido: 13 feb 2024 @ 15:33

Retorno: -11.34%

Señal anterior: feb 13 - 09:30

Señal anterior: Comprar

Retorno: 2.98 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States...

Stats
Volumen de hoy	290 330
Volumen promedio	439 330
Capitalización de mercado	1.03B
EPS	$0 ( 2024-03-19 )
Próxima fecha de ganancias	( $-0.740 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.82
ATR14	$0.00800 (0.08%)

Volumen Correlación

Largo: 0.01 (neutral)

Corto: 0.65 (weak)

Signal:(56.361) Neutral

Immatics N.V. Correlación

10 Correlaciones Más Positivas
RMRM	0.966
RXT	0.929
SWAV	0.925
UCBI	0.922
NFE	0.918
CCRN	0.917
NVTSW	0.916
GBCI	0.915
FIBK	0.914
THTX	0.914

10 Correlaciones Más Negativas
MLCO	-0.927
EZGO	-0.926
RXDX	-0.925
FWONK	-0.922
BRAC	-0.92
LUNA	-0.918
HWCC	-0.917
BKNG	-0.917
MLVF	-0.916
MOMO	-0.915

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immatics N.V. Correlación - Moneda/Commodity

0.45
( neutral )

0.43
( neutral )

0.00
( neutral )

0.44
( neutral )

0.36
( neutral )

-0.20
( neutral )

Immatics N.V. Finanzas

Annual	2023
Ingresos:	$54.00M
Beneficio Bruto:	$-64.67M (-119.76 %)
EPS:	$-1.200

FY	2023
Ingresos:	$54.00M
Beneficio Bruto:	$-64.67M (-119.76 %)
EPS:	$-1.200

FY	2022
Ingresos:	$172.83M
Beneficio Bruto:	$66.05M (38.22 %)
EPS:	$0.550

Financial Reports:

No articles found.

Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.